Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPeach State Health Plan Etanercept Coverage Update…
    Ask Trek AI about this page
    ModifiedPeach State Health PlanPolicy CP.PHAR.250

    Clinical Policy: Etanercept (Enbrel)

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy CP.PHAR.250 alerts

    Get alerted when Policy CP.PHAR.250 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and utilization rules for etanercept (Enbrel) for Peach State Health Plan (Medicaid) members across labeled rheumatologic and dermatologic indications.

    Policy Summary
    PayerPeach State Health Plan
    PolicyClinical Policy: Etanercept (Enbrel)
    Policy CodePolicy CP.PHAR.250
    Change TypeMaterial updates: biosimilar preferencepJIA criteriaapproval duration
    Effective DateAug 16, 2025
    Next Review DateAug 26, 2025
    Key ActionSubmit prior authorization with supporting clinical documentation showing required prior trials or contraindications and indicate any adalimumab product trial as specified.
    SourceLink
    POLICY UPDATE CHANGES

    Per July SDC, added criteria requiring use of one adalimumab product and listed multiple preferred adalimumab products for all indications.

    2Q 2025 review removed minimum cJADAS-10 > 8.5 requirement for pJIA initial criteria and removed requirement for decrease in cJADAS-10 for continued therapy.

    Extended initial approval durations to 12 months for chronic conditions.

    2Q 2026 annual review: no significant changes; references reviewed and updated.

    12 monthsInitial approval duration
    50 mgMax maintenance dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Ages 2+
    Minimum pediatric age
    Multiple adalimumabPreferred agents added
    boxed warningsSafety highlights

    Coverage Criteria Summary

    Initial Therapy — Ankylosing Spondylitis

    Covered when ALL of the following are met

    Ankylosing Spondylitis initial criteria: 1. Diagnosis of ankylosing spondylitis (AS).; 2. Age ≥ 18 years.; 3. Prescribed by or in consultation with a rheumatologist.; 4. Failure of at least TWO NSAIDs at up to maximally indicated doses, each used ≥ 4 weeks unless adverse effects/contraindicated/previous biologic failure.; 5. Member meets both of the following, each used > 3 consecutive months unless adverse effects/contraindicated: (a) failure of ONE adalimumab product (examples: Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp) unless history of failure of two TNF blockers; (b) if not responded/intolerant to one or more TNF blockers, trial of tofacitinib/tofacitinib XR unless cardiovascular risk outweighs benefit.; 6. No combination use with biological DMARDs or JAK inhibitors.; 7. Dose does not exceed 50 mg every week.

    Prior authorization may be required for adalimumab products and tofacitinib/tofacitinib XR

    Initial Therapy — Plaque Psoriasis

    Covered when ALL of the following are met

    Plaque Psoriasis initial criteria: 1. Diagnosis of moderate-to-severe plaque psoriasis as evidenced by (a) ≥ 3% total body surface area OR (b) involvement of hands, feet, scalp, face, or genital area.; 2. Prescribed by or in consultation with a dermatologist or rheumatologist.; 3. Age ≥ 4 years.; 4. One of: (a) failure of a ≥ 3 month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥ 3 month trial of cyclosporine or acitretin at up to maximally indicated doses; (c) intolerance/contraindication to methotrexate/cyclosporine/acitretin and failure of phototherapy.; 5. If ≥ 18 years, one of: (a) failure of a ≥ 3 month trial of ONE adalimumab product (examples: Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp) unless history of failure of two TNF blockers; (b) history of failure of two TNF blockers.; 6. For age ≥ 6 years, failure of a ≥ 3 month trial of one ustekinumab product unless adverse effects/contraindicated.; 7. No combination use with biological DMARDs or JAK inhibitors.; 8. Dose limits: (a) Adults: 50 mg twice weekly for 3 months then 50 mg every week; (b) Pediatrics: weight-based dosing per Appendix E (weight <63 kg: 0.8 mg/kg every week; weight ≥63 kg: 50 mg every week).

    Prior authorization may be required for adalimumab and ustekinumab products

    Initial Therapy — PJIA

    Covered when ALL of the following are met

    Polyarticular Juvenile Idiopathic Arthritis (pJIA) initial criteria: 1. Diagnosis of polyarticular juvenile idiopathic arthritis (PJIA) evidenced by ≥ 5 joints with active arthritis.; 2. Prescribed by or in consultation with a rheumatologist.; 3. Age ≥ 2 years.; 4. One of: (a) failure of a ≥ 3 month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥ 3 month trial of leflunomide or sulfasalazine; (c) for sacroiliitis/axial involvement, failure of a ≥ 4 week NSAID trial; (d) documentation of high disease activity.; 5. Failure of ALL of the following, each used for ≥ 3 months unless adverse effects/contraindicated: (a) ONE adalimumab product (examples: Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp) unless history of failure of two TNF blockers; (b) Actemra (tocilizumab); (c) if not responded/intolerant to one or more TNF blockers, tofacitinib unless cardiovascular risk outweighs benefit.; 6. No combination use with biological DMARDs or JAK inhibitors.; 7. Dose limits: adults 50 mg every week; pediatrics weight-based dosing per Appendix E (weight <63 kg: 0.8 mg/kg every week; weight ≥63 kg: 50 mg every week).

    Prior authorization may be required for adalimumab products, Actemra, and tofacitinib

    Initial Therapy — Psoriatic Arthritis

    Covered when ALL of the following are met

    Psoriatic Arthritis initial criteria: 1. Diagnosis of psoriatic arthritis (PsA) or juvenile PsA (JPsA).; 2. Prescribed by or in consultation with a dermatologist or rheumatologist.; 3. Age ≥ 2 years.; 4. For members ≥ 18 years, failure of ALL of the following, each used ≥ 3 months unless adverse effects/contraindicated: (a) ONE adalimumab product (examples: Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp) unless history of failure of two TNF blockers; (b) Otezla/Otezla XR; (c) one ustekinumab product; (d) if not responded/intolerant to one or more TNF blockers, tofacitinib/tofacitinib XR unless cardiovascular risk outweighs benefit.; 5. For ages 6–17, failure of a ≥ 3 month trial of both Otezla/Otezla XR and one ustekinumab product unless adverse effects/contraindicated.; 6. No combination use with biological DMARDs or JAK inhibitors.; 7. Dose limits: adults 50 mg every week; pediatrics weight-based dosing per Appendix E (weight <63 kg: 0.8 mg/kg every week; weight ≥63 kg: 50 mg every week).

    Prior authorization may be required for adalimumab, Otezla, ustekinumab, and tofacitinib products

    Initial Therapy — Rheumatoid Arthritis

    Covered when ALL of the following are met

    Rheumatoid Arthritis initial criteria: 1. Diagnosis of rheumatoid arthritis (RA) per ACR criteria.; 2. Prescribed by or in consultation with a rheumatologist.; 3. Age ≥ 18 years.; 4. One of: (a) failure of a ≥ 3 month trial of methotrexate at up to maximally indicated doses; (b) intolerance/contraindication to methotrexate and failure of a ≥ 3 month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine).; 5. Failure of ALL of the following, each used ≥ 3 months unless adverse effects/contraindicated: (a) ONE adalimumab product (examples: Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, adalimumab-fkjp) unless history of failure of two TNF blockers; (b) Actemra (tocilizumab); (c) if not responded/intolerant to one or more TNF blockers, tofacitinib/tofacitinib XR unless cardiovascular risk outweighs benefit.; 6. Documentation of baseline disease activity assessment with CDAI or RAPID3.; 7. No combination use with biological DMARDs or JAK inhibitors.; 8. Dose does not exceed 50 mg every week.

    Prior authorization may be required for adalimumab products, Actemra, and tofacitinib/tofacitinib XR

    Other / Off-label pathway

    Other uses

    Other diagnoses/off-label pathway: 1. If the drug label changed within the last 6 months and the change is not yet reflected in this policy, follow CP.PMN.255 (Medicaid no-coverage-criteria) or CP.PMN.16 (non‑formulary) as applicable.; 2. If the requested use is not listed in Section III and criterion 1 does not apply, refer to the off-label use policy CP.PMN.53 (Medicaid).

    Continued Therapy — Continuation authorized when ALL of the following are met

    Continuation authorized when ALL of the following are met

    Continued therapy general: 1. Member is currently receiving the medication via Centene benefit or previously met initial approval criteria, or has continuity of care as applicable.; 2. For RA: member is responding positively to therapy as evidenced by decrease in CDAI or RAPID3 from baseline, or if CDAI reassessment cannot be performed, submission of RAPID3 showing similar or improved disease severity; for other indications: member is responding positively to therapy.; 3. Member does not have combination use with biological DMARDs or JAK inhibitors.; 4. If request is for a dose increase, new dose does not exceed 50 mg every week.

    Combination therapy with other biologic disease‑modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants is not authorized. This includes, but is not limited to, concurrent use with other tumor necrosis factor (TNF) antagonists, interleukin pathway inhibitors, Janus kinase inhibitors (JAKi), anti‑CD20 agents, selective co‑stimulation modulators, integrin receptor antagonists, tyrosine kinase 2 inhibitors, and sphingosine‑1‑phosphate receptor modulators due to additive immunosuppression and increased risk of neutropenia and serious infections.

    Non‑FDA‑approved indications not specifically addressed in this Etanercept (Enbrel) policy are excluded from coverage unless there is sufficient documentation of efficacy and safety consistent with the Peach State off‑label use policy CP.PMN.53 (Medicaid) or other applicable evidence‑of‑coverage documents.

    Etanercept is contraindicated in patients with sepsis. The policy also highlights boxed warnings for serious infections and malignancies, which should be considered when evaluating suitability for therapy.

    Historical revisions to the policy reiterate the prohibition on combination use of etanercept with another biologic DMARD or a JAK inhibitor. This requirement was carried forward into Sections I and II during prior annual reviews and template updates to emphasize single‑agent biologic use.

    Requests for combination therapy with other bDMARDs or JAK inhibitors will be considered not medically necessary because of additive immunosuppression and the associated increased risk of serious infections and neutropenia.

    The policy reiterates that combination use with another biologic DMARD or a JAK inhibitor is not allowed; this prohibition has been explicitly restated in revision notes and applied across indicated sections.

    Inclusion or exclusion of procedure and supply codes in this policy does not by itself guarantee coverage. Providers must refer to the specific indication‑level not‑medically‑necessary statements elsewhere in the policy and use current professional coding guidance when submitting claims.

    Initial Therapy — Indication Specific

    Initial therapy — Indication-specific initial therapy criteria require diagnosis, specialist involvement, age minimums, prior therapy failures or contraindications

    Indication-specific initial therapy criteria require diagnosis, specialist involvement, age minimums, prior therapy failures or contraindications

    Indication-specific requirements (summary): Initial therapy criteria for AS, PsO, PJIA, PsA, and RA include: confirmed diagnosis; prescriber specialty requirement (rheumatologist or dermatologist as specified); minimum age thresholds (eg, RA/AS adults ≥18; PJIA/PsA/JPsA ≥2; PsO ≥4 years); required prior trials and durations of conventional therapies (eg, NSAIDs, methotrexate, cyclosporine, leflunomide, sulfasalazine) and specified biologics or small molecules (eg, adalimumab products, Actemra, ustekinumab, Otezla, tofacitinib) unless contraindicated or intolerant; prohibition of combination use with other biologic DMARDs or JAK inhibitors; and dose limits (commonly ≤50 mg/week).

    See Sections I.A–I.E for full per‑indication logic

    Initial therapy — Aligned with FDA dosing and policy sequencing preferences

    Aligned with FDA dosing and policy sequencing preferences

    Dosing alignment and sequencing:

    Continued Therapy Requirements

    Continued therapy — Continued therapy requirements

    Continued therapy requirements

    Continued therapy: 1. Member is currently receiving medication via Centene benefit or previously met initial approval criteria, or has applicable continuity of care.; 2. Documentation of clinical response: for RA, decreased CDAI or RAPID3 from baseline or justification with RAPID3 if CDAI reassessment not possible; for other indications, member is responding positively to therapy.; 3. No combination use with biological DMARDs or JAK inhibitors.; 4. Dose increases must not exceed 50 mg every week.

    Continuation therapy — Allowed when prior response and safety monitoring show continued benefit and dosing remains within labeled limits

    Continuation is allowed when prior response and safety monitoring show continued benefit and dosing remains within labeled limits

    Continuation therapy operational criteria: Continued therapy requires documentation of clinical response (examples: reduction in joint pain/swelling, improvement in ESR/CRP, improved activities of daily living) and adherence to single‑agent biologic use; dosing must remain within labeled limits (commonly ≤50 mg/week).

    Step Therapy and Required Prior Trials

    Step descriptionRequired prior trials / preferences
    Progressive step prior to Enbrel initiation
    Documented failure or intolerance of conventional therapies (examples: ≥2 NSAIDs each ≥4 weeks for AS; ≥3 months of methotrexate or another conventional DMARD where specified), followed by failure of specified biologic(s) or small molecules as listed for the indication (e.g., failure of one adalimumab product unless history of failure of two TNF blockers; trial of tofacitinib/tofacitinib XR when indicated).
    Policy changeEffect on prior trials for certain indications
    July SDC: added requirement to use specified preferred agents prior to etanercept for some indications
    Examples: AS — required use of Taltz and Xeljanz/XR (per July SDC); PsO — required use of Taltz; pJIA — required use of Actemra and Xeljanz/XR; PsA — required use of Otezla, Taltz, Xeljanz/XR (note: some of these requirements were later removed or modified per subsequent SDC updates).
    Revision summaryAdalimumab preference / required trial
    Per July SDC and subsequent updates, policy operationalized adalimumab-class preference and redirection across indications.
    Requirement: failure of ONE adalimumab product (examples listed as preferred: Yusimry, Hadlima, unbranded adalimumab-fkjp, unbranded adalimumab-adaz, adalimumab-adbm, Simlandi, adalimumab-aaty) is required in many indications unless member has history of failure of two TNF blockers; prior authorization may be required for adalimumab products.

    Provider Actions and Documentation Requirements

    Prior Authorization

    Prior authorization required for Enbrel and certain comparators

    Prior authorization is required for etanercept (Enbrel) per the policy and prior authorization may also be required for certain referenced comparator products (for example, adalimumab products, tofacitinib/tofacitinib XR, Actemra, ustekinumab, Otezla) as noted in indication-specific criteria. Providers should follow indication-specific submission requirements when requesting authorization.

    • Prior authorization may be required for adalimumab products and tofacitinib/tofacitinib XR (AS) [[see policy notes in chunks 4, 7].]
    • Prior authorization may be required for adalimumab and ustekinumab products for PsO (chunk 5).
    • Prior authorization may be required for adalimumab products, Actemra, and tofacitinib for PJIA and RA (chunks 7, 11).
    Prior Authorization

    Reference J1438 for physician‑administered etanercept

    When etanercept is administered by a physician in a supervised setting, providers should reference HCPCS code J1438 on authorization and claims and submit clinical justification consistent with dosing, contraindications, and therapeutic alternative use.

    Coding and Billing References

    Referenced HCPCS CodesHCPCS
    J1438Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self‑administered)
    Referenced HCPCS CodesHCPCS
    J1438Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)
    Vial quantity dosing thresholds for pediatric dosing — mapping of mg to vial counts
    ≤ 25.99 mgVial Quantity Recommendation = 1 vial of 25 mg/0.5 mL
    26 to 52.49 mgVial Quantity Recommendation = 1 vial of 50 mg/mL
    Guidance contextDose rounding guidance applies to PJIA, pediatric PsO, and JPsA per Appendix E
    Billing Rule

    Use J1438 for physician‑supervised office administration

    When etanercept is administered under direct physician supervision in the office setting, J1438 may be used; coding and site-of-care assumptions differ for self-administered dosing.

    Biosimilar and Class-Level Preferred Agent Direction

    Billing Rule

    Preferred adalimumab biosimilars listed; trial required

    The policy lists multiple preferred adalimumab biosimilars and notes that failure of one adalimumab product is required in many indications unless the member has a history of failure of two TNF blockers.

    • Preferred adalimumab examples include Hadlima, Simlandi, Yusimry, adalimumab-aaty, adalimumab-adaz, adalimumab-adbm, and adalimumab-fkjp.
    Billing Rule

    Policy requires use of one adalimumab product (preferred examples listed)

    Per SDC updates, the policy added criteria requiring use of one adalimumab product and lists specific adalimumab reference/biosimilar examples as preferred agents for certain indications.

    Billing Rule

    Adalimumab class-level preferred-agent requirement

    At the class level, the policy requires trial or use of one adalimumab product and provides preferred examples (e.g., Yusimry, Hadlima, adalimumab-adbm, Simlandi, unbranded adalimumab products) to be tried or used prior to redirection for specified indications.

    Definitions and Scoring

    CDAI — clinical disease activity index
    AcronymCDAI = Clinical Disease Activity Index
    PurposeComposite index for assessing RA disease activity using 28-joint swollen/tender counts plus patient and physician global assessments
    Scoring rangeScore range 0–76 with interpretation: ≤2.8 remission; >2.8–10 low; >10–22 moderate; >22 high
    PJIA — polyarticular juvenile idiopathic arthritis
    DefinitionPJIA = polyarticular juvenile idiopathic arthritis
    Diagnostic criterion (policy)PJIA evidenced by ≥5 joints with active arthritis required for initial therapy criteria

    Quantity Limits and Typical Dosing

    Enbrel (etanercept) — typical quantity/strength noted (50 mg)
    Typical strength50 mg (single-dose prefilled syringe, autoinjector, cartridge)
    Other presentations25 mg/0.5 mL single-dose prefilled syringe and single-dose vial also available
    Product nameEnbrel (etanercept)

    Site of Care and Administration

    Billing Rule

    Office administration coding note (J1438)

    When etanercept is administered under direct physician supervision in an office setting, J1438 may be used; self-administered dosing requires different coding and site-of-care assumptions.

    Billing Rule

    Office/infusion center coding implication for J1438

    J1438 may be used for physician‑administered etanercept under direct supervision in office or infusion center settings but is not appropriate for self‑administered use.

    Background

    Etanercept (Enbrel) is a tumor necrosis factor (TNF) blocker indicated for several inflammatory rheumatologic and dermatologic conditions including rheumatoid arthritis, psoriatic arthritis (including juvenile forms), ankylosing spondylitis, plaque psoriasis, and polyarticular juvenile idiopathic arthritis. The policy aligns authorization with indication‑specific dosing regimens and prior‑therapy sequencing consistent with labeled use.

    Policy Summary
    PayerPeach State Health Plan
    PolicyClinical Policy: Etanercept (Enbrel)
    Policy CodePolicy CP.PHAR.250
    Change TypeMaterial updates: biosimilar preferencepJIA criteriaapproval duration
    Effective DateAug 16, 2025
    Next Review DateAug 26, 2025
    Key ActionSubmit prior authorization with supporting clinical documentation showing required prior trials or contraindications and indicate any adalimumab product trial as specified.
    SourceLink
    On This Page
    Coverage Criteria SummaryInitial Therapy — Indication SpecificContinued Therapy RequirementsStep Therapy and Required Prior TrialsProvider Actions and Documentation RequirementsCoding and Billing ReferencesBiosimilar and Class-Level Preferred Agent DirectionDefinitions and ScoringQuantity Limits and Typical DosingSite of Care and AdministrationBackground
    Initial therapy should follow FDA‑labeled dosing for the specific indication and consider policy-preferred sequencing (including preferred adalimumab products and other specified preferred agents per SDC updates) when applicable.

    Appendix I contains dosing tables; revisions in Coding Implications note preferred-agent sequencing (chunk 37).

    Initial therapy updates — Initial therapy updates captured in revision notes

    Initial therapy criteria updates captured in revision notes

    Initial approval duration update: Initial approval durations for chronic conditions have been extended to 12 months.12 months

    Policy-wide change noted in revisions (chunk 41).

    pJIA initial criteria update: For pJIA, removal of requirement for minimum cJADAS-10 > 8.5 and removal of baseline 10‑joint cJADAS-10 documentation in initial criteria (Appendix I updated per 2019 ACR guidance).

    2Q 2025 update referenced in revisions (chunk 39/41).

    Dosing/Indication-specific coverage

    Covered when dosing and indication align with labeled regimens and policy-preferred sequencing for indicated conditions.

    RA dosing: Etanercept dosing for RA: 25 mg SC twice weekly or 50 mg SC once weekly; maximum 50 mg/week.

    chunk 32

    PsA dosing: Adults: 25 mg SC twice weekly or 50 mg SC once weekly; Pediatrics: 0.8 mg/kg SC once weekly for weight <63 kg; maximum 50 mg/week.

    chunk 32

    AS dosing: Weight ≥63 kg: 50 mg SC once weekly; maximum 50 mg/week.

    chunk 32

    PJIA dosing: Weight <63 kg: 0.8 mg/kg SC once weekly; Weight ≥63 kg: 50 mg SC once weekly; maximum 50 mg/week.

    chunk 32

    PsO dosing: Adults: initial 50 mg SC twice weekly for 3 months then maintenance 50 mg SC once weekly; Pediatrics: 0.8 mg/kg SC once weekly for weight <63 kg; maximum 50 mg/week.

    chunk 32

    Notable coverage criteria updates

    Policy-level coverage direction and notable criteria changes include:

    Adalimumab preference and redirection: Per SDC updates, policy requires use of one adalimumab product and lists multiple preferred adalimumab products (examples include Yusimry, Hadlima, unbranded adalimumab-fkjp, unbranded adalimumab-adaz, adalimumab-adbm, Simlandi, unbranded adalimumab-aaty).

    applies across indications as specified in Section I

    Initial approval duration change: Initial approval durations for chronic conditions have been extended to 12 months.12 months

    policy-wide change noted in revisions (chunk 41)

    pJIA criteria removal: For pJIA, removal of minimum cJADAS-10 > 8.5 requirement for documentation of high disease activity and removal of requirement for decrease in cJADAS-10 from baseline for continued therapy.

    Appendix I updated per 2019 ACR guidance

    chunks 27,37

    pJIA continued therapy changes

    Continued therapy criteria updated for pJIA

    pJIA continued therapy change: Removed requirement that continued therapy response be evidenced by a decrease in cJADAS-10 from baseline; Appendix I updated with pJIA disease activity information per 2019 ACR guidance.

    2Q 2025 revision noted in Coding Implications (chunk 39)

    • J1438 is listed as the HCPCS code for etanercept 25 mg for physician‑administered injections (informational) (chunk 36/37).
    • Use J1438 only when drug is administered under direct physician supervision; not for self‑administered dosing (chunks 21, 36).
    Prior Authorization

    Initial authorization duration and HCPCS code

    Initial authorizations for chronic indications have been extended to 12 months. The policy lists J1438 as the HCPCS code for the 25 mg etanercept injection (informational) to be used when the drug is physician‑administered.

    • Approval duration for initial and continued therapy for chronic conditions: 12 months (chunks 4, 7, 8, 9, 11 and revision notes in chunk 41).
    • J1438 = Injection, etanercept, 25 mg (may be used when administered under direct physician supervision) (chunk 36).
    Step Therapy

    Document required prior trials and durations

    Many indications require documented failure of specified prior therapies before Enbrel is authorized; required prior trials and minimum durations are indication‑specific and must be documented.

    • Examples: failure of ≥2 NSAIDs each ≥4 weeks for AS (chunk 4); failure of ≥3 months of MTX for PsO and RA (chunks 5, 11).
    • Many indications require failure of one adalimumab product (unless history of failure of two TNF blockers) and trials of other specified agents (chunks 4, 7, 9, 11).
    Step Therapy

    Follow preferred‑agent and step‑preference requirements

    The policy includes preferred‑agent and step‑preference language requiring use of specified preferred agents for some indications; providers must follow the policy’s required sequence when requesting authorization.

    • Per SDC updates, the policy requires use of one adalimumab product and lists preferred adalimumab products across indications (chunk 37).
    • Specific preferred agents were added for certain indications (examples in chunk 37 and Appendix B in chunk 21).
    Step Therapy

    Required trial/use of preferred agents before Enbrel in some indications

    For certain indications, the policy now requires trial or use of specified preferred agents (for example, adalimumab products) prior to authorization of etanercept; document prior use or failure as specified.

    • Policy revisions require trial/use of one adalimumab product and list multiple preferred adalimumab examples (chunk 37).
    • Some indications previously required specific preferred agents (Taltz, Xeljanz, Otezla) though subsequent SDC changes have modified these requirements (chunk 41).
    Documentation Required

    Submit supportive clinical documentation with authorization request

    Providers must submit supporting clinical documentation (such as office chart notes, lab results, or other clinical information) demonstrating that the member meets all approval criteria when requesting authorization.

    • Documentation must support diagnosis, prior therapy trials/failures, specialist involvement, and clinical response or disease activity measures where required (chunk 3).
    • pJIA documentation requirements were modified in 2Q2025; see Appendix I for updated disease activity information (chunk 39/37).
    Documentation Required

    Document dosing and product formulation details

    When requesting authorization, document the dosing regimen and product formulation (for example, SC prefilled syringe, autoinjector, vial sizes) and indicate the exact dose and frequency being requested.

    • Appendix I lists available product presentations (25 mg/0.5 mL prefilled syringe, 50 mg/mL autoinjector, 25 mg vial, etc.) and labeled dosing by indication (chunk 33, chunk 32).
    • Ensure submitted dosing aligns with labeled regimens (examples: 50 mg SC once weekly; pediatric 0.8 mg/kg once weekly) (chunk 32).
    Documentation Required

    pJIA documentation changes — updated Appendix I and removed cJADAS‑10 threshold

    For polyarticular juvenile idiopathic arthritis (pJIA), the policy removed the prior requirement to document a minimum cJADAS‑10 > 8.5 in the initial criteria and updated Appendix I disease activity information per 2019 ACR guidance; follow the revised Appendix I when documenting pJIA disease activity.

    • 2Q 2025 review removed minimum cJADAS‑10 > 8.5 requirement and removed requirement for decrease in cJADAS‑10 for continued therapy; see Appendix I for updated scoring guidance (chunks 39, 32).
    Denial Risk

    Denial risk: missing documentation or requests for combination biologic/JAK therapy

    Requests that do not include documentation demonstrating that the member has met all approval criteria, or requests for combination use with other biological DMARDs or JAK inhibitors, will be denied as not authorized.

    • Combination use with bDMARDs or other potent immunosuppressants (including TNF antagonists, interleukin agents, and JAK inhibitors) is not authorized (chunk 16).
    • Provider submissions must document all required prior trials, contraindications/intolerances, and specialist involvement as applicable (chunk 3).
    Billing Rule

    Coding does not guarantee coverage — verify coding guidance before claims

    Inclusion or exclusion of codes in the policy does not guarantee coverage; providers should reference the most up‑to‑date professional coding guidance prior to claim submission and ensure claims use current coding.

    • Coding referenced in this policy is informational only; verify coding guidance before submitting claims (chunk 36).
    • J1438 may be used when drug is physician‑administered under direct supervision; it is not for self‑administered use (chunk 36).
    Note

    Confirm coding and claim submission guidance

    Before submitting claims, providers should verify current coding guidance and confirm that the HCPCS/CPT/other codes used for etanercept and related services are appropriate, as inclusion in the policy is informational and not a guarantee of reimbursement.

    • Providers should reference the most up‑to‑date sources of professional coding guidance prior to claim submission (chunk 36).
    Billing Rule

    J1438 use for physician‑administered etanercept (not self‑administered)

    J1438 may be used for physician‑administered etanercept under direct supervision in office or infusion center settings; it should not be used for self‑administered dosing.

    Pediatric dosing
    Weight <63 kg: 0.8 mg/kg SC once weekly; Weight ≥63 kg: 50 mg SC once weekly (maximum 50 mg/week)
    tumor necrosis factor — TNF
    AbbreviationTNF = tumor necrosis factor
    Class examplesTNF blockers include etanercept (Enbrel), adalimumab and biosimilars, infliximab and biosimilars, certolizumab, golimumab
    Clinical relevanceEtanercept is a TNF blocker used to treat RA, PsA, AS, PsO, PJIA; avoid combination use with other bDMARDs/JAK inhibitors due to additive immunosuppression
    Disease activity indices referenced for RA and JIA — CDAI / RAPID3 / cJADAS-10
    Indices listedCDAI / RAPID3 / cJADAS-10
    Use casesCDAI and RAPID3 used for RA baseline assessment and continued therapy; cJADAS-10 used for juvenile arthritis disease activity per ACR guidance
    Scoring referencesAppendices G–I provide score ranges and disease state interpretations for CDAI, RAPID3, and cJADAS-10
    HCPCS code for etanercept 25 mg injection (informational) — J1438
    HCPCS codeJ1438
    DescriptionInjection, etanercept, 25 mg
    Usage noteMay be used for physician‑administered etanercept under direct supervision (not for self‑administered use); codes informational only